This study will investigate the pharmacokinetics and safety of RoActemra/Actemra (tocilizumab) in patients less than 2 years old with active systemic juvenile i diopathic arthritis. Patients will receive RoActemra/Actemra infusions every 2 w eeks. The anticipated time on study treatment is 12 weeks.